These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30354917)

  • 1. Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.
    Tang S; Zhang Q; Tang X; Chen D; Zhang F; Liu J; Wei W; Liu D
    J Int Med Res; 2019 Feb; 47(2):641-652. PubMed ID: 30354917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
    Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM
    JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
    J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
    Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ
    J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
    Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
    Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
    Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
    Sukumar JS; Sardesai S; Ni A; Williams N; Johnson K; Quiroga D; Ramaswamy B; Wesolowski R; Cherian M; Stover DG; Gatti-Mays M; Pariser A; Sudheendra P; George MA; Lustberg M
    Cancer Med; 2024 Jun; 13(12):e7317. PubMed ID: 38895891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
    Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
    Francis PA
    Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.